The FDA on May 13, 2026, approved an oral combination of INQOVI® with Venetoclax for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. INQOVI® is a product of Taiho Oncology.
Bottom Ad
Advertisement
Subscribe
